linkedin

Press Releases

Press Releases

Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022

BPI%20220929%20PR(EN)_1040_585%20copy.png


Two distinctive platforms will streamline the antibody development process.
With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies. 
DEVELOPICK™ provides early insight and selection guidance to save time and cost to maximize efficiency. 
  
Incheon, S. Korea, Sept. 29, 2022 – Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year’s BioProcess International Conference and Exhibition in Boston.

S-DUAL™ is a high-yield bispecific antibody platform with a 99% chain-pairing success rate. Its unique asymmetrical structure reduces risks associated with chemistry, manufacturing and control (CMC), and thus ensures high binding affinity among chains to produce high titer and purity for optimized manufacturability. 

DEVELOPICK™ is a rapid developability assessment platform that systematically screens molecules at an early development stage to identify candidates with the best potential for advancement to Investigational New Drug (IND) and Biological License Application (BLA). Requiring only 20 milligrams of material, the assessment platform enables clients to conduct a robust risk assessment for unsorted drug candidates within a month, guiding them to the path of biotherapeutic development success.  

“We are excited to showcase our innovative platforms at the BioProcess International Conference this week,” said John Rim, CEO of Samsung Biologics. “Through these new development technologies, we provide early insight and ensure higher yield of molecules, ultimately enabling clients to reach commercialization much more efficiently.”

Samsung Biologics is also hosting a speaking session to discuss its new approach to bispecific antibody development and has presented scientific posters on a number of topics throughout the event. To find out more, get in touch with a representative at Booth #837 or through the website at samsungbiologics.com.
BPI%20220929%20PR(EN)_1040_585%20copy.png


Two distinctive platforms will streamline the antibody development process.
With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies. 
DEVELOPICK™ provides early insight and selection guidance to save time and cost to maximize efficiency. 
  
Incheon, S. Korea, Sept. 29, 2022 – Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year’s BioProcess International Conference and Exhibition in Boston.

S-DUAL™ is a high-yield bispecific antibody platform with a 99% chain-pairing success rate. Its unique asymmetrical structure reduces risks associated with chemistry, manufacturing and control (CMC), and thus ensures high binding affinity among chains to produce high titer and purity for optimized manufacturability. 

DEVELOPICK™ is a rapid developability assessment platform that systematically screens molecules at an early development stage to identify candidates with the best potential for advancement to Investigational New Drug (IND) and Biological License Application (BLA). Requiring only 20 milligrams of material, the assessment platform enables clients to conduct a robust risk assessment for unsorted drug candidates within a month, guiding them to the path of biotherapeutic development success.  

“We are excited to showcase our innovative platforms at the BioProcess International Conference this week,” said John Rim, CEO of Samsung Biologics. “Through these new development technologies, we provide early insight and ensure higher yield of molecules, ultimately enabling clients to reach commercialization much more efficiently.”

Samsung Biologics is also hosting a speaking session to discuss its new approach to bispecific antibody development and has presented scientific posters on a number of topics throughout the event. To find out more, get in touch with a representative at Booth #837 or through the website at samsungbiologics.com.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please sign up to view the post.

Please sign up to view the post.
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION